Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease

Bibliography

• Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012;12:56
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20(11):563–9
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16(2):139–49
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004;306(5701):1506–7
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Molecular Metabolism 2014;3(3):221–9
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009;9(6):805–10
   PubMed Web of Science ®Google Scholar
• Adams AC, Coskun T, Rovira AR, et al. Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 2012;7(5):e38438
   PubMed Web of Science ®Google Scholar
• Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 2012;56(6):2404–11
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8(3):235–53
   PubMed Web of Science ®Google Scholar
• Nishimura T, Utsunomiya Y, Hoshikawa M, et al. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999;1444(1):148–51
   PubMed Web of Science ®Google Scholar
• Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11(10):729–35
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB–PGC-1a pathway. Cell Metab 2011;13(6):729–38
   PubMed Web of Science ®Google Scholar
• Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260(6):530–6
   PubMed Web of Science ®Google Scholar
• Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17(13):1581–91
   PubMed Web of Science ®Google Scholar
• Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7 alpha-hydroxylase gene expression. Hepatology 2009;49(1):297–305
   PubMed Web of Science ®Google Scholar
• Marcelin G, Jo YH, Li X, et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 2013;3(1):19–28
   PubMed Web of Science ®Google Scholar
• Barutcuoglu B, Basol G, Cakir Y, et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011;41(4):390–6
   PubMed Web of Science ®Google Scholar
• Mráz M, Lacinová Z, Kaválková P, et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-a agonist treatment. Physiol Res 2011;60(4):627–36
   PubMed Web of Science ®Google Scholar
• Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7(11):1189–94
   PubMed Web of Science ®Google Scholar
• Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011;17(6):1322–7
   PubMed Web of Science ®Google Scholar
• Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298(3):G440–5
   PubMed Web of Science ®Google Scholar
• Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145(6):2594–603
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005;115(6):1627–35
   PubMed Web of Science ®Google Scholar
• Wöhrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF23 signaling and regulating FGF23 expression in bone. J Bone Miner Res 2011;26(10):2486–97
   PubMed Web of Science ®Google Scholar
• Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012;26(4):312–24
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331(6024):1621–4
   PubMed Web of Science ®Google Scholar
• Wu X, Ge H, Baribault H, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res 2013;54(2):325–32
   PubMed Web of Science ®Google Scholar
• Wu X, Ge H, Lemon B, et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA 2009;106(34):14379–84
   PubMed Web of Science ®Google Scholar
• Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143(5):1741–7
   PubMed Web of Science ®Google Scholar
• Stejskal D, Karpisek M, Hanulova Z, et al. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 2008;68(6):501–7
   PubMed Web of Science ®Google Scholar
• Fang Q, Li H, Song Q, et al. Serum fibroblast growth factor 19 levels are decreased in chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 2013;36(9):2810–14
   PubMed Web of Science ®Google Scholar
• Ryan KK, Kohli R, Gutierrez-Aguilar R, et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013;154(1):9–15
   PubMed Web of Science ®Google Scholar
• Ciofi P. The arcuate nucleus as a circumventricular organ in the mouse. Neurosci Lett 2010;487(2):187–90
   PubMed Web of Science ®Google Scholar
• Warne JP, Xu AW. Metabolic transceivers: in tune with the central melanocortin system. Trends Endocrinol Metab 2013;24(2):68–75
   PubMed Web of Science ®Google Scholar
• Qureshi HA, Pearl JA, Anderson KA, et al. Fibroblast growth factor 19 activates the unfolded protein response and mitogen-activated protein kinase phosphorylation in H-69 cholangiocyte cells. J Liver 2014;3(3):158
   Google Scholar
• Kim I, Ahn SH, Inagaki T, et al. Differential regulation of bile acid homeostasis by the farnesoid x receptor in liver and intestine. J Lipid Res 2007;48(12):2664–72
   PubMed Web of Science ®Google Scholar
• Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007;282(37):26687–95
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J Cell Physiol 2008;215(1):1–7
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009;284(15):10023–33
   PubMed Web of Science ®Google Scholar
• Kir S, Kliewer SA, Mangelsdorf DJ. Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol 2011;76:130–44
   Google Scholar
• Shin DJ, Osborne TF. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem 2009;284(17):11110–20
   PubMed Web of Science ®Google Scholar
• Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2(4):217–25
   PubMed Web of Science ®Google Scholar
• Yu C, Wang F, Kan M, et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000;275(20):15482–9
   PubMed Web of Science ®Google Scholar
• Zhang J, Li HT, Fang QC, et al. Role of fibroblast growth factor 19 in maintaining nutrient homeostasis and disease. Biomed Environ Sci 2014;27(5):319–24
   PubMed Web of Science ®Google Scholar
• Ge H, Baribault H, Vonderfecht S, et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One 2012;7(3):e33603
   PubMed Web of Science ®Google Scholar
• Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010;285(8):5165–70
   PubMed Web of Science ®Google Scholar
• Obici S, Feng Z, Tan J, et al. Central melanocortin receptors regulate insulin action. J Clin Invest 2001;108(7):1079–85
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Pai R, Ferrando RE, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008;27(1):85–97
   PubMed Web of Science ®Google Scholar
• Wu AL, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One 2011;6(3):e17868
   Google Scholar
• Ge H, Zhang J, Gong Y, et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem 2014;289(44):30470–80
   PubMed Web of Science ®Google Scholar
• Wu X, Ge H, Lemon B, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci USA 2010;107(32):14158–63
   PubMed Web of Science ®Google Scholar
• Huang X, Yang C, Luo Y, et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007;56(10):2501–10
   PubMed Web of Science ®Google Scholar
• Morton GJ, Matsen ME, Bracy DP, et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 2013;123(11):4799–808
   PubMed Web of Science ®Google Scholar
• Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160(6):2295–307
   PubMed Web of Science ®Google Scholar
• Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012;12:56
   PubMed Web of Science ®Google Scholar
• Patman G. Liver: a variant of FGF19 protects the liver from cholestatic injury without inducing cancer. Nat Rev Gastroenterol Hepatol 2014;11(10):579
   PubMedGoogle Scholar
• Rizzo M, Nikolic D, Banach M, et al. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des 2014;20(31):4953–60
   PubMed Web of Science ®Google Scholar
• Gao X, Wang G, Zhang W, et al. Expression of pulmonary aquaporin 1 is dramatically upregulated in mice with pulmonary fibrosis induced by bleomycin. Arch Med Sci 2013;9(5):916–21
   Web of Science ®Google Scholar
• Gluba A, Banach M, Mikhailidis DP, et al. Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. In Vivo 2009;23(5):797–812
   PubMed Web of Science ®Google Scholar
• Gundogan K, Bayram F, Gedik V, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci 2013;9(2):243–53
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol 2014;46(5):947–61
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ding X, Fang C, et al. Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure. Mol Pharmacol 2014;85(1):139–47
   PubMed Web of Science ®Google Scholar